To facilitate the detection of carriers of a hemizygous survival motor neuron (SMN) exon 7 deletion we have modified the quantitative SMN exon 7 assay described by McAndrew et al (1997). The major changes include quantitative analysis of the amount of SMN exon 7-specific fluorescently-labelled PCR product on an automated sequencer, and the monitoring of the completeness of a DraI digestion necessary to distinguish the PCR products of exons 7 of SMN and its copy gene. In our method the amount of SMN exon 7 PCR product is compared with the amount of a co-amplified PCR product of the retinoblastoma (RB1) exon containing a DraI restriction site. By co-amplification using the same primers of plasmids included in the reaction as internal standards containing SMN exon 7 with a 36-nucleotide deletion and RB1 exon 13 with a 19-nucleotide deletion, respectively, the relative amplification efficacy can be monitored. The assay has been validated in 63 ascertained carriers and 28 ascertained non-carriers. The sensitivity of the test is approximately 97%, the specificity approaches 100%. In four out of six SMA patients without a homozygous deletion we detected a hemizygous deletion. The implications of the use of this assay for carrier testing and for confirmation of the clinical diagnosis of SMA are discussed.
Introduction
With a prevalence of about 1/10 000, 1,2 and a carrier frequency of 1/40-1/60 3,4 the proximal spinal muscular atrophies (SMAs) are among the most frequent autosomal recessive hereditary disorders. Patients can be classified clinically into three groups: acute, intermediate, and mild (SMA types I, II, and III,respectively). 5, 6 The SMA 5q13 region shows a complex structure at the genomic level, including a 500-bp duplication and inversion. 7 The survival motor neuron (SMN) gene is present in at least one telomeric (SMN1) and one centromeric copy (SMN2) per chromosome in normal (non-carrier) individuals. 7 The two SMN genes (SMN1 and SMN2) are highly homologous and contain only five base-pair differences within their 3' ends. 8 The differences in exons 7 and 8 are used to distinguish SMN1 and SMN2 in direct diagnosis of SMA. Deletions of the SMN1 gene located at chromosome 5q13 appear to be directly involved in SMA, 7 since exon(s) 7 (and 8) of SMN1 are undetectable in over 95% of patients, irrespective of their clinical type, 7, [9] [10] [11] [12] either as a result of homozygous deletions, or because of conversion of sequences of SMN1 to those in the SMN2 gene. 7, [11] [12] [13] [14] [15] [16] The identification of several small mutations in the SMN1 gene in patients without a deleted or sequenceconverted SMN1 allele provides strong evidence that this gene is the primary SMA-determining gene. 7, 8, [17] [18] [19] [20] [21] [22] [23] [24] [25] The clinical phenotype of SMA appears to be determined by the underlying mutational mechanism. Most cases of SMA type I result from homozygous gene-deletion events, whereas the milder forms of the disease, SMA types II and III, result mostly from gene conversion of SMN1 to SMN2, in SMA type II a gene conversion event in one allele in addition to a hemizygous deletion event in the other allele, or gene conversions in both alleles in SMA type III. 13, 15, 16, 26, 27 As a result, patients suffering from the milder forms of SMA carry more copies of the SMN2 gene. 
Patients, materials and methods

SMA patients and DNA isolation
Clinical assessment of the SMA patients has been described elsewhere. 10 The diagnosis of SMA was in agreement with the strict criteria established by the International SMA Consortium. 30 As ascertained carriers, 63 parents of multiple affected children with a homozygous SMN exon 7 deletion have been investigated. As likely non-carriers, 31 siblings of SMA patients with two non-risk 5q haplotypes as shown by linkage analysis using flanking informative markers have been studied. DNA was isolated from peripheral blood by the salting out method, 31 or from chorionic villus samples by organic extraction.
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Synthesis of internal standards
Two internal standards (IS) were constructed for standardisation and monitoring of the amplification efficiency of both competitive PCR reactions in the SMN1 copy number assay (see Figure 1) ) and SMN7IS (TCGATAGATACAGATA-TATCGATATCTGTTTTAGTTTTTCTTC CTTCC-3') primers for SMN-IS and 20 ng each of RBex13F (5'-ATTACACAG-TATCCTCGACA-3') and RBIS13 (5'-TATACGAACTGGAAA-GATGCCTATAGTACCACGAATTACAATG-3') primers for RB-IS, and 0.5 U AmpliTaq polymerase (Perkin Elmer, Foster City, CA, USA). The reactions were denatured at 95°C for 5 min, then run for 33 cycles at 95°C 1 min, 55°C 2 min, and 72°C 3 min (Perkin Elmer 9600 thermocycler). The products were subcloned into pCR2.1 (Invitrogen, Carlshad, CA, USA), and the plasmids were purified according to standard procedures. As internal standards 15 000 genome equivalents of intact plasmids were used in the copy-number assay. Note that the SMN-IS does not contain a DraI site.
SMN1 Copy-number assay
Two competitive amplifications are performed in a multiplex PCR reaction. The genomic DNA concentration was determined by spectrofluorometric analysis. Per reaction approximately 50 ng DNA was used (about 15 000 genome equivalents) in the presence of 3 µl of a mixture containing 5000 molecules/µl of SMN-IS and RB-IS each with 20 ng each of fluorescently-labelled R111 and non-labelled X7-Dra (5'-CCTTCCTTCTTTTTGATTTTG TTT-3' 28 primers for SMN products, and 20 ng each of RBex13F and fluorescentlylabelled RBex13R (5'-TATACGAACTGGAAAGATGC-3') primers for RB products, respectively. The 25 µl reaction contained 3 mM MgCl 2 , 200 µM each dNTP, and 0.5 U AmpliTaq polymerase (Perkin Elmer). The reactions were denatured at 95°C for 5 min, then run for 24 cycles at 95°C for 1 min, 55°C for 2 min, and 72°C for 3 min (Perkin Elmer 9600 thermocycler). The PCR products (15 µl) were digested with 10 U DraI overnight at 37°C. The digested samples were run on a 6% denaturing polyacrylamide gel on an automated sequencer Carrier testing in SMA y H Scheffer et al(ALF, Pharmacia, Sweden) and the peak intensity was quantified by measuring the Area Under the Curve (AUC). Completeness of DraI digestion was monitored by absence of undigested products of 237 bp (RB exon 13 product) and 218 bp (RB-IS). Since there are two copies of RB per genome, the genomic SMN1/genomic RB ratio was used to determine the relative copy number of SMN1 for all samples, and corrected for differences in amplification efficiency of the two competitive PCR reactions by multiplication using a factor RB-IS/SMN-IS. 33 This corrected ratio is normalised for the mean of the ratios obtained in two standard reference samples (from individuals carrying two copies of SMN1 exon 7) that were included in all gels. Also included in all gels were two reference samples from hemizygous SMN1 exon 7 deletion carriers and a blank sample lacking genomic DNA. Non-carriers have a normalised and corrected ratio over 0.75; carriers have a normalised and corrected ratio under 0.75. All reactions were duplicated. Only those results have been taken into account of which the duplicate reaction results did not differ by more than 20%.
Results
Carriers
In 61 out of 63 samples from parents of multiple-affected children with SMA, a normalised and corrected SMN1/RB genomic ratio compatible with a single SMN1 exon 7 copy was found. A representative analysis is shown in Figure 2 . The average ratio observed in these 61 samples was 0.54 ± 0.12 (mean ± SD) ranging from 0.27 to 0.70. The values of the normalised and corrected SMN1/RB genomic ratio for these 61 carriers are shown in Figure 3 . In two of 63 samples a normalised and corrected SMN1/RB genomic ratio compatible with two SMN1 exon 7 copies was found (1.12 and 1.24; the two left-hand samples in Figure 3 ).
Figure 1
Amplification strategy of the quantitative SMN exon 7 analysis. Deletion products of SMN exon 7 (36 bp deletion) and RB1 exon 13 (19 bp deletion) have been generated by PCR, and subcloned into pCR2.1. These plasmids have been added as internal standards (SMN-IS and RB-IS, respectively). Three PCR-products are generated by the SMN primers: SMN1, SMN2, and SMN-IS. SMN1 and SMN2 can be separated by DraI digestion. Two PCR-products are generated by the RB1 primers: RB-genomic, and RB-IS. The RB-genomic and the RB-IS contain a DraI restriction site, enabling the monitoring of the completeness of digestion. The forward SMN primer and the reverse RB primer are fluorescently end-labelled. The length of the PCR-products in base pairs is indicated.
Carrier testing in SMA
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Non-carriers
In three samples the test results obtained were obviously unreliable (see Discussion). In 27 out of 28 samples from ascertained carriers, a normalised and corrected SMN1/RB genomic ratio compatible with two SMN1 exon 7 copies was found. The average of this ratio observed in these 27 samples was 1.11 ± 0.25 (mean ± SD) ranging from 0.78 to 1.79. The values of the normalised and corrected SMN1/RB genomic ratio for these 27 non-carriers are shown in Figure 3 . In one sample the SMN1/RB genomic ratio is 1.79, differing more than 2 SD from the average value of 1.11, most likely indicating that this sample may in fact contain three SMN1 exon 7 copies. In one of 28 samples a normalised and corrected SMN1/RB genomic ratio compatible with a single SMN1 exon 7 copy was found (0.28). This sample contained DNA isolated from a chorionic villus sample. After revaluation of a DNA sample isolated from leukocytes from the same meanwhile healthy born individual, we detected a normalised and corrected SMN1/RB ratio compatible with two SMN1 copies.
Patients
Six patients with clinical confirmed proximal SMA without a homozygous SMN exon 7 deletion were analysed. In four of these six patients a normalised and corrected SMN1/RB genomic ratio compatible with a single SMN1 exon 7 copy was found. A representative analysis is shown in Figure 4 . The presence of a hemizygous deletion of SMN1 exon 7 was confirmed in one parent in all four cases. In one case out of four hemizygous deleted SMA patients, we identified in the other allele a point mutation which creates a novel splice site in exon 4 of SMN1 and thus disturbs the reading frame of the SMN1 gene (submitted). 34 In two out of six patients, including one with a haploidentical healthy sibling, a normal SMN exon 7 intensity was detected.
Discussion
Technique Our method of determining the number of SMN1 genes in a given DNA sample implies two improvements when compared with the original procedure described by McAndrew et al. 21 Because the DNA sequences are amplified with a fluorescently end-labelled primer in each amplicon, an automated sequencer can be used for fragment separation and quantification. In addition, we substituted an amplicon containing a DraI restriction site, namely exon 13 of the retinoblastoma (RB1) gene for the original genomic reference amplicon -an exon from the cystic fibrosis conductance transmembrane regulator (CFTR) gene, which contained no DraI restriction. This allows monitoring of the completeness of DraI digestion necessary to distinguish exon 7 of SMN1 from that of SMN2. 28 It may also be noted that rare individuals with an RB1 deletion have a phenotype, ie retinoblastoma, and will therefore be recognised as RB1 deletion carriers, whereas CFTR deletion carriers such as described by Morral et al 33 will not, since cystic fibrosis is a recessive disorder. Furthermore, we calculated a corrected SMN1/RB ratio based on the generally applicable quantitative PCR method described by Celi et al. 35 This calculation takes into account a possible difference in amplification efficiency for the two competitive PCR reactions used. We noted that reliable results are only obtained if the signals of the RB-IS, SMN-IS, and RB-genomic amplification products do not differ greatly. As a rule of thumb, the signal with the lowest intensity may not be less than 50% of the highest signal of the three PCR products. In Figure 3 it can be seen that no overlap in values of the SMN1/RB ratio for carriers and noncarriers was observed (except for the two samples of carriers showing SMN1/RB values consistent with two SMN1 genes; see also Carriers). To verify whether gel deviations exist, the SD within each gel has also been calculated for carriers and non-carriers, and the resulting SDs were summed and divided by the number of gels. For carriers a mean SD per gel of ± 0.08 was calculated, which is considerably lower than the SD of ± 0.12 for the analysis as a whole. This was also observed for the non-carriers, where a mean SD per gel of ± 0.20 was calculated, compared with an SD of ± 0.25 for the analysis as a whole. This analysis using batch statistics indicates that for clinical use the most reliable results will be obtained by comparison of samples within a single gel. At least one known normal reference sample and one known carrier reference sample should be included per gel.
Carriers
The identification of two individuals with a double SMN1 dose among 63 ascertained carriers can be explained in several ways. Theoretically, a germ line mosaicism for an SMN1 exon 7 (and 8) deletion cannot be ruled out. The DNA samples originate from parents with multiple-affected offspring, which might be explained by the existence of more than one germ cell harbouring an SMN1 exon 7 (and 8) deletion not present in DNA from leukocytes of these individuals. Case 1 is a father of multiple-affected children (false paternity highly unlikely based on data from microsatellite analysis in the family), whereas case 2 is a mother of multiple-affected children. However, since Wirth et al 36 have
shown that de novo deletions in SMN1 occur during meiotic cell divisions in the majority of cases, and germline mosaicism is thought to occur in mitotic cell divisions during early 
Non-carriers
In three samples the tests were obviously unreliable because the duplicated reaction results differed by more than 20%. The identification of one individual with a single SMN1 dose out of 28 ascertained non-carriers can also be explained in several ways. Theoretically, a double crossover between the markers used for initial linkage analysis in this family cannot be ruled out (likelihood less than 1%). However, since this case represents a DNA sample isolated from a chorionic villus sample, we considered it more likely that because of the difference in DNA isolation procedures used for leukocytes and chorionic villus samples, an incorrect ratio was determined, possibly due to degradation of genomic DNA during storage of the sample. We reanalysed DNA isolated from leukocytes from this meanwhile healthy born individual. A normalised and corrected SMN1/RB genomic ratio compatible with a two-SMN1 exon 7 copy was found, confirming that the SMN1/RB ratio was determined incorrectly due to the quality of the chorion villus DNA sample. We conclude from this finding that the specificity of the test after revaluation of the aberrant sample is close to 100% (95% confidence interval 87-100%). In conclusion, only DNA samples isolated by the same procedure can reliably be compared with reference samples using this technique. Samples of DNA isolated from chorionic villi cannot be stored prior to quantitative analysis, since endonucleases are apparently not rigorously inactivated by the extraction procedure used here.
Consequences for risk calculations
In applications for carrier testing of relatives of an SMA index patient with an ascertained homozygous SMN1 exon 7 (and 8) deletion, a sensitivity of 97% should be used.
Assuming an a priori risk of 1/2 (uncles and aunts of patients), or 2/3 (healthy siblings of patients), and a specificity of the test of 100%, a non-carrier test result would lead to a posteriori risks of approximately 2.9% (uncles and aunts) and 5.7% (siblings), respectively. If a hemizygous deletion could be detected in parents of an SMA patient prior to a carrier test in an unaffected sibling, and the test result in this sibling were negative, then being a carrier would be virtually excluded. For carrier testing of random individuals without positive family history of SMA assuming an a priori risk of 1/45 of being a carrier of any mutant SMN1 allele and a specificity of the test of 100%, a test sensitivity of 95% should be used. If an SMN1/RB ratio compatible with two SMN1 genes is found, the a posteriori risk of being a carrier is 0.11. If an SMN1/RB ratio compatible with one SMN1 gene is found, the a posteriori risk of being a carrier is 99.89%.
Patients
The two patients in whom we could not identify a hemizygous SMN1 exon 7 deletion reflects the fact that proximal SMA-like diseases exist. We consider it less likely, however, that locus heterogeneity exists in true recessive proximal SMA, since non-5q-haploidentical affected sibs have never been identified. Given the current limited knowledge of SMN function the possibility of dominant mutant SMN alleles cannot be excluded.
Since 95% of proximal SMA patients have a homozygous SMN1 exon 7 (and 8) deletion, this test may confirm the clinical diagnosis in the vast majority of cases. However, when no homozygous deletion is observed, the detection of a hemizygous deletion using the test described here will give a strong suggestion of confirmation of the clinical diagnosis in virtually all cases, since it follows from the HardyWeinberg equilibrium that less than 0.6% of patients will have a mutant non-deletion SMN1 allele on both chromosomes. In case of a hemizygous deletion, it cannot be excluded, however, that the individual is merely a carrier of an SMN1 exon 7 (and 8) deletion. It also follows that whenever no hemizygous deletion is found in a patient suspected on clinical grounds of having SMA, the diagnosis of 5q-linked SMA can be practically rejected. It is our experience that on scrutinising the clinical data, or on clinical revaluation of a patient without a homozygous SMN deletion, a different clinical diagnosis can be made in almost all cases.
